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A B S T R A C T
Personalized medicine, one of the main promises of the Human Genome Project (HGP) that began three decades
ago, is now a new therapeutic paradigm. With its arrival the era of developing drugs to suit all patients, yet often
having to withdraw a promising new one because a minority of patients was at risk, even though it had proved
valuable for the majority was consigned to history as were trial-and-error strategies being the predominant
means of tailoring therapy. But how did it originate and the earliest examples emerge? Is it true that the first
personalized diagnostic test was the companion test for Herceptin®? This account of a remarkable journey from
genomic and translational research to therapeutic and diagnostic innovations, describes how sequencing the
human growth hormone (hGH) locus provided proof of principle for HGP-inspired personalized medicine.
Sequencing this locus and the resultant biomanufacture of HGH and the development of a test capable of de-
tecting which patients would benefit from its administration helped silence the skeptics who questioned the
validity of such an approach. The associated companion diagnostic was created four years before the invention
of the HercepTest® (registered as the first companion diagnostics ever developed). By cultivating genomic re-
search with passion and pursuing its applications, we and many others contributed to the emergence of a new
diagnostics industry, the discovery of better actionable gene-targets and to a revitalized pharmaceutical industry
capable of developing safer and more effective therapies. In combination, these developments are beginning to
fulfill the promise of the HGP, offering each patient the opportunity to adopt the right treatment at the correct
dosage in an opportune manner.
1. Fishing a gene for my genetic journey: the chorionic
somatomammotropin gene from human placenta
Molecular cloning, invented in the early years of the decade of
1970, arose an international fever and race to clone human genes. For
the rest of that memorable decade, and throughout at least the first half
of the next one, many genes were “fished.” And their study exploded a
golden era of human molecular genetics and unleashed a new bio-
technology revolution. The first ones, or so-called low-hanging fruits,
were those whose messenger ribonucleic acids or mRNAs were abun-
dant in the tissues in which they were quite active or from tissues that
were easily accessible. Perhaps the best example in molecular genetics
was the β-globin gene since peripheral blood cells are both full of its
mRNA and easy to get a hold of, while in biotechnology they were
human growth hormone and insulin.
At the beginning of the decade of 1980, I was a graduate student in
the Biochemistry Department of the University of Texas Health Science
Center at Houston, in its then called MD Anderson Hospital and Cancer
Center. Being in one of the largest medical centers in the world, the
fever also got me, and I, too, wanted to clone a gene.
As early as the summer of 1978, I was extracting mRNA from the
human placenta and, through its translation in a cell-free system (in
vitro), I noticed that one of its most abundant mRNA species was that of
the then called human placental lactogen (later baptized as human
chorionic somatomammotropin or HCS). I frequently visited the library
to learn, from Nature or Science magazines mainly, which new gene
was reportedly being cloned. One day, I read that Peter Seeburg, who
had just moved from the University of California at San Francisco to the
recently launched, first biotech company of the world, Genentech, Inc.,
had just cloned a fragment of the complementary DNA (cDNA) to the
mRNA of this placental hormone thanks to an ingenious trick. He had
converted all placental mRNA species to cDNA, and, as a bulk, treated
them with restriction enzymes. Next, he separated the restricted pro-
ducts by gel electrophoresis and cut out, cloned and characterized the
most abundant, discrete cDNA band. This band, of around 500 base
pairs (bp), turned out to be the central region of the hCS cDNA. Since he
knew that HCS and human growth hormone (HGH) were highly similar
proteins, he moved quickly to use his partial hCS cDNA clone as a probe
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or hook to pull out, from a cDNA library made of a hypophyseal ade-
noma cDNA, the cDNA of the hGH gene, putting it aside to complete the
cloning of the full-length hCS cDNA.
Peter kindly shared with me his probe and I used it to screen the
human placental cDNA library I had just constructed. I pulled several
cDNA clones very easily, including one harboring the full-length hCS
cDNA. This way I was one step away from finally cloning the hCS gene
myself. Using my clone, Vincent Kidd in our laboratory screened a
human genomic library and pooled several positive gene clones that
were characterized by making preliminary restriction maps of each one.
I quickly identified among them the one matching restriction mapping
features of my hCS cDNA. I incubated both, the gene and full-length
cDNA, under conditions that favored heteroduplex formations between
them (suggested by Donald Robberson, an expert in electron micro-
scopy). When Donald and I examined them in the electron microscope,
we noticed four small “bubbles” (see Fig. 1). We interpreted them as
corresponding to an equal number of sequences in the gene which were
absent in the cDNA, which means we had just discovered the four small
introns that interrupt the message hidden in this split gene [1].
2. Pioneering genomics research: hGH locus, a chapter of our
hereditary encyclopedia
The multiple genes pulled from the human genomic library
screening with my hCS cDNA proved to be a cluster of genes which I
was able to assemble into a pentagenic hGH locus and together with
Mary Harper we revealed its position in bands q22–24 of the long arm
of chromosome 17, being the first time ever that a so-called single copy
gene was assigned its chromosomal position in the human karyotype.
Besides the emblematic gene named hGH-N, which is the one re-
sponsible for the production of HGH in the somatotrophs of the hypo-
physis, this locus of our genome happened to contain an additional GH-
type gene, hGH-V, which in the placenta produces a variant of the hy-
pophyseal hormone that is postulated to replace it exclusively during
the gestation period of pregnant women. It also includes two placental
genes whose cDNAs I had pulled out during the screening of my pla-
cental cDNA library and discovered that, surprisingly, their mRNAs
code for an identical mature HCS. Finally, there was this third hCS gene
whose corresponding cDNA I could not identify among the clones I had
fished out during the screening of my placental cDNA library, nor by
trying at least two other cDNA characterization methods [2].
To explain the mystery of this last hCS gene, I turned again to Peter
Seeburg to share with him my findings and he arranged with my doc-
toral adviser, Grady F. Saunders, for me to spend time in his laboratory
at Genentech to sequence entirely and for the first time this mysterious
gene, which turned out to harbor a mutation at the beginning of its
second intron known to render the genes presenting it inactive or
pseudogenes. We baptized it as CSH-Like or simply CSH-L.
Before returning from Genentech to my laboratory in Houston, Peter
and his colleague, Elson Chen, invited me to contribute this gene se-
quence to an unusually ambitious and weird project, which involved
sequencing the entire hGH locus, genes and their intergenic and
flanking regions and of the locus itself, which in total we estimated that
would encompass over 60,000 nucleotides (see Fig. 2).
I gladly accepted their invitation and, back at my bench in
Saunders's laboratory, I continued to curate the crude sequences I had
just brought from Seeburg's laboratory. Reading the genes was rela-
tively easy; however, assembling the intergenic pieces separating them
was a difficult task, since they harbored half a hundred repetitive ele-
ments of the Alu-family. Nevertheless, besides the sequence of CSH-L, I
helped too by having solved the pentagenic structure in which this and
the other four genes of the locus were assembled. When we completed
curing the locus sequences (see Fig. 3) about five years later (it took us
so many years since it was a side project for all of us, especially for me
since by then I was already in Mexico starting my own laboratory), we
had decoded an equivalent to a chapter of an enormous encyclopedia
which we now know it consists of almost twenty-five thousand chap-
ters, which as a whole conceals the secrets of our species: our genome.
While this project was going on, I graduated, went to France to do a
postdoc, and returned to Mexico to start my own laboratory. In 1989,
the job was finally done, and the manuscript was submitted and readily
accepted for publication in Genomics [3], the leading journal of the
nascent discipline with this same name: genomics. Our achievement
was soon noticed by the scientific community and mentioned in the
magazine Science as a world record for the largest piece of human
genomic DNA ever sequenced, becoming the first evidence that, if
technology could be greatly improved, it would be feasible to launch a
project that would involve sequencing the entire human genome, which
was later known as the Human Genome Project or simply HGP.
But what did our quixotic achievement teach us about the use of
sequencing the whole genome which took place almost fifteen years
later? Well, that when you have the genomic sequence of your genetic
research model, you have uniquely valuable information that you could
dig into or do its “mining” to design experiments to solve the ultimate
questions about the origin, composition, functioning, and consequences
of dysfunctions of our hereditary instructions; even more, and with a bit
of creativity and the proper challenges, to exploit it for deriving in-
ventions!
In our case, wishing to prove in my laboratory the usefulness of
having sequenced our tiny piece (0.0016%) of the human genome, we
launched ambitious projects that led to the achievement of a myriad of
inventions and discoveries that we never imagined would have such an
impact later on in medicine and biotechnology [4]. Here I have chosen
two inventions of my laboratory that illustrate the value of genomic
information in advancing medicine and biotech.
Fig. 1. Anatomy of the genes harbored in the hGH locus. By hybridizing a strand of the gene with its complementary DNA and searching for the resulting het-
eroduplexes in the electron microscope, we discovered four introns (A through D) splitting the gene into five exons.
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3. Initial mining of the hGH locus sequence for advancing
biomedical research
How is it that, being encoded by genes showing more than 90%
similarity in their flanking regions (and even more in their coding
ones), being so close to each other in the genome, and having been
derived from a common ancestor not so long ago, they display such
marked differences in their pattern of expression both spatial (different
tissues) and temporal (at different times of our lives)-specific?
Not only is hGH-N set apart by its hypophysis-specific expression,
but also by the fact that its expression is shut down in pregnant women
to allow the placental members of the family to control the maternal
metabolism to ensure the survival of the human fetus. Likewise, not
only is the expression of the so-called placental genes restricted almost
exclusive to the placenta, but it is also synchronized with the devel-
opment of the placenta itself.
So, where do the secrets for regulation of their tissue-specificity and
temporarily-governed gene expression reside? When in addition to the
five coding sequences of the genes in the hGH locus, we consider their
introns and the space separating them (intergenic regions) and add up
the flanking sequences we adventured to read too, it turns out that this
gene family encompasses approximately 66,000 nucleotides (66 kb). It
was precisely by dissecting these gene-flanking DNA zones that we were
Fig. 2. Sequencing the hGH locus of our human genome. The locus was isolated as a pair of large clones fished out from a genomic library with the cDNA probe. To
facilitate its sequencing, it was spread into a few dozen smaller clones. The assembled and curated sequence was deposited in the GenBank sequence database with
accession number J03071.
Fig. 3. The hGH locus chapter of the human hereditary encyclopedia. This over
sixty-six thousand string of nucleotides is equal to a chapter of the monumental
encyclopedia that is our genome.
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able to discover the main mechanisms regulating its differential tissue-
specific expression, as illustrated in Fig. 4. One such mechanism is ex-
emplified by Pit-1 (pituitary transcription factor 1, also known as
growth hormone factor-1) acting on the promoter of hGH-N to induce
the transcription of this gene in the pituitary but unable to do so on the
rest of the genes (GH-V and CSHs) as a result of their promoters con-
taining a region of 0.3 kb, referred to as element P, to which certain
placental proteins bind, interfering with Pit-1's binding. Another me-
chanism is through the enhancer, which is an expression control ele-
ment that potentiates transcription of the adjacent gene(s). In the case
of the hGH locus, this happens to be located right after the hCSH genes,
thus explaining the amazingly high production of CSH by the human
placenta at the end of pregnancy, with quantities surpassing one gram
per day! Therefore, to control the spatial (different tissues) and tem-
poral (only during pregnancy) expression of a gene family, the human
genome devotes ten times more DNA than that needed for specifying
the hormones codified in this family (see Fig. 4).
Seeking to further exploit this discovery in order to contribute to the
advance of the emerging field of viral vectors for gene therapy, we took
advantage of the tissue specificity of the gene's promoter to control the
replication mechanism of adenoviral vectors so as to develop re-en-
gineered viruses that were capable of selectively replicating within
cultured hypophyseal tumor cells that were then burst by induction of
cell lysis, while leaving any other type of normal cells intact. When we
were exploring to move this discovery to the preclinical stage, we
started a similar project for the development of a similar treatment but
for cervical cancer, that was more rapidly and successfully tested in an
animal model. This incursion in the field of gene therapy of my la-
boratory led by my former student Augusto Rojas and by then my
fellow departmental colleague, finally led to a collaborative project
with colleagues from Baylor College of Medicine in Houston that al-
lowed us to implement the first clinical trial for cancer gene therapy
ever carried out in Latin America. In it, we administered also an ade-
noviral vector but carrying a gene from another virus that contributes
the unique biochemical capability of phosphorylating a nucleotide
analog that when incorporated in the recipient cell halts its DNA re-
plication (precisely for this reason this approach is referred as suicidal
gene therapy) [5].
4. Industrial exploitation of our chapter of the human genomic
encyclopedia: rHGH
By the time the publication describing our seminal work on geno-
mics came out, I was struggling in Mexico to consolidate my laboratory
in a kind of avant-garde scientific desert. My mission, I was convinced,
was to introduce and cultivate Human Molecular Biology, which back
then was the most promising scientific discipline in medicine. Even
though I was madly working on consolidating my laboratory, I could
not resist the temptation of bragging our world record. But, to whom?
Not only was there no other molecular biologist in a 500-mile radius
(the approximate distance from Monterrey to Houston) with whom I
could discuss the relevance of our achievement, but most of the few
professionals around me were skeptical clinicians from our nearby
University Hospital. And since they were more concerned with saving
lives, they invariably reproached me when I presumed my world record
repeatedly questioning me: what possible use, in the daily battle they were
fighting at the hospital, could such genomic information that I had in my
hands have?
My new environment was indeed unique. On one side I was strug-
gling to stay in the world-class academia and thus was working like
crazy to establish the new research and graduate programs of my young
laboratory so that my existence and that of the new discipline I brought
with me would be noticed by the administration. This battle, I was
fighting from my modest bunker in a corner of an abandoned section of
the Department of Biochemistry at the University of Nuevo Leon
Medical School in Monterrey, Mexico. On the other side and just across
the street were all these rocket-science questioners in the clinical de-
partments of the said hospital, where I had managed to make many new
Fig. 4. Differential gene expression control in the hGH locus. Despite their high structural resemblance, close genomic proximity and, to some extent, overlapping
functionalities, only the hGH-N gene is active in the pituitary gland while the rest are active in the placenta. The secret to this spatial expression difference lays in the
genes' promoters acting as switches and responding to diverse gene activating and repressing factors.
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friends. Soon, some of them challenged me to prove that our achieve-
ment had at least some practical use in the clinic. I gladly and arro-
gantly accepted their challenge.
The opportunity to prove to them that our pioneer genomic research
indeed had some useful application in medicine came the day I least
expected, but luckily soon enough. One day, our Dean called upon me
to his office to inform me he had invited the state governor to visit the
hospital and he wanted me to be present during the visit. He also in-
formed me that he was planning to invite a few other colleagues from
among the most restless and vivacious researchers in the faculty that he
respected and truly wanted to help their careers. Moreover, he also
mentioned that he was expecting for all of us to take this unique op-
portunity to impress the governor with our sophisticated research
projects. He had planned that, if we could make a positive impression,
the governor could contribute funds to the hospital and part of them
would be used to support our work.
My colleagues, when exposing their plans to the governor, ended up
making a request for large and expensive pieces of equipment (the
larger and more expensive the better!); I guess with the rationale that if
their work was in the forefront of science, it demanded such sophisti-
cated tools. I instead, and to the surprise of the governor, simply asked
him to instruct the State Attorney to grant me prompt access to the
pituitary gland of cadavers of people who died from traumatic accidents
and that are typically sitting at the morgue while their relatives show
up to claim them. The next day I received a call from the State Attorney
office with a positive reply to my unusual request. Soon, I had the
glands from some twenty cadavers, collected shortly after an excep-
tional fast-track autopsy of the dead bodies just after their arrival at the
forensic laboratory in our hospital, immediately put in dry ice, and
quickly transported to the ultralow freezer of my laboratory. There
were long nights due to grant deadlines when this messenger from the
forensic laboratory appeared in my office to hand me a new gland. I felt
like Victor Frankenstein and pictured the messenger as Igor,
Frankenstein’s assistant. '
Why did I want the hypophysis of cadavers, you ask? Well, to
emulate what Peter Seeburg had so ingeniously done to clone the hGH
cDNA mentioned above which, after a law settlement with UCSF for
several millions of dollars, was licensed to Genentech to produce re-
combinant (r) HGH. Good enough, the approach worked perfectly and
from the cloned, restriction enzyme-digested, total cDNA from the ca-
daveric hypophysial mRNA (see Fig. 5), we easily isolated our own
version of the hGH cDNA [6].
But what was this gland's genetic instruction useful for? Well, our
body uses it to command the synthesis of HGH, which is why I thought
of using it to reprogram a microbial biotechnological host to produce
rHGH. This with the aim of eventually offering a national, technological
alternative to the few ones from abroad rendering commercial rHGH
(including the one my friend Peter had developed for Genentech). This
biotech blockbuster was badly needed by our pediatricians and en-
docrinologists to treat patients suffering from the partial absence of this
hormone, so they could offer them the chance to achieve normal height
and thus escape from the otherwise inevitable destiny of suffering from
severe dwarfism.
We tried out our idea with the new yeast, Pichia pastoris, which was
quickly dominating the list of favorite biotechnological host for genetic
engineering applications. And it worked beautifully for the first time!
We got transformed yeast to produce and secrete, into the culture
media, rHGH, which we proved to be identical to that present in the
human hypophysis and even more: it was abundantly secreted into the
fermented yeast media in its biologically active form [7].
Our new method to produce rHGH was so novel and innovative that
we convinced the USPTO and another patenting office in Europe and
Japan, in addition to the one in Mexico, to grant us the patent, pro-
tecting our invention (see Fig. 6). With it in our hands and after having
successfully demonstrated it worked at pilot plant scale, we were able
to raise the interest of the first Mexican biotech firm to license our
technology to produce rHGH in Mexico. This way I had proven to my
fellow clinicians that genomics can lead to the availability of a - I was
hoping - more affordable rHGH.
We followed our success of using the cDNA transformation of yeast
for producing rHGH to reprogram yeasts using the cDNAs of the re-
maining genes of the hGH locus so that they could produce the rest of
the hormones encoded by these genes. We did the same with cDNAs
cloned from a dozen plus animal GHs and even prolactins and CSHs.
These genetic engineering experiments resulted in the world's largest
collection of recombinant somatolactogens, a name collectively given
to all these different types of body growth and metabolic regulators.
5. Medical exploitation of our genomic data: diagnosing HGH
absence
Even though I felt I had succeeded in proving to my fellow clin-
icians, who were skeptical at first, that genomic information had, in
fact, some practical value by attempting to help them with an
Fig. 5. Cloning the hGH gene's complementary DNA.
Having opportune access to the pituitary glands from
cadavers allowed us to clone the genetic instruction
our body uses to synthesize HGH. Its deficiency by
the dysfunctioning of the corresponding gene causes
dwarfism, which can be reverted by replacement
therapy with the biosynthetic or recombinant (r)
hormone as Tracy profited of it back in the early
1980s.
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alternative biotechnology-produced hormone, some of them were not
completely convinced, yet. Thus, they gave me a second challenge: to
help them predict which children would respond to replacement therapy with
rHGH and to distinguish them from those few that unexplained till then
wouldn't. The only piece of information we had in face of this challenge
was that those children unable to respond had no reduced amounts of
the hormone, but rather lacked it totally and when treated with the
biotechnologically produced version, their immune system rejects it,
since it recognizes it as a foreign protein (or antigen, in this case) and
makes antibodies to neutralize it. With my over optimism of the value
of the genomic information I treasured in the hGH locus, I once again
accepted this new challenge by them of not only explaining this enigma
but also contributing a way to genetically identify these exceptional
children and to alert the pediatricians over the useless of prescribing
them rHGH.
Fortunately, my laboratory in Monterrey, Mexico, was by then
(early 1990´s) some kind of sanctuary of science, attracting the best
youth to the glamorous human molecular biology I had introduced to
my country upon my arrival from the best laboratories in the world that
were advancing this new discipline. Also, to my fortune, I had just re-
turned from Chile, where I lectured at a Human Genome workshop that
exposed me to the newly-invented polymerase chain reaction (PCR). In
addition, some of my best students were being seduced by bioinfor-
matics and were practicing it with their modest, personal computers by
reprogramming, at night, powerful computers at the International
Center for Genetic Engineering and Biotechnology Center of Trieste,
Italy. So, not only did I have all these new wonderful tools at hand, but
also, of course, the unique advantage of being among a handful of in-
dividuals in the world in possession of the complete sequence of the
hGH genomic locus. Thus, I assigned to one of my students, as his BSc
thesis subject, to come up with a PCR test to differentiate patients that
had the hGH gene intact from those lacking it. This quest would be the
laboratory explanation for the former kind of patients' positive response
to the hormone replacement therapy, and for the latter type of patients'
rejection of it. We soon had the scheme of the diagnostic assay that we
proved right using cloned versions of the genes that we mixed to re-
constitute an artificial hGH genomic locus. Next, I turned to my most
harsh critics in the pediatric clinics and requested them to provide me
with blind samples, i.e. samples whose data I did not have and thus
didn't know their respondent/non-respondent condition, from ten of
their young patients clinically diagnosed with severe growth retarda-
tion. Sure enough, during the first application of our newly designed
genetic test, we spotted one patient that lacked the hGH gene and
predicted that they would be a non-responder [8]; my fellow clinicians
later confirmed this was indeed the case (see Fig. 7).
6. Did you say a test that predicts the outcome of treatment with
rHGH? You have invented the first companion diagnostics, you
dummy!1
It was by wanting to prove to skeptical clinicians that pioneer
genomic research could have practical benefits, that the first ever
Fig. 6. First ever production of rHGH in yeast. Cloned hGH cDNA was introduced in the genome of yeast whose fermentation resulted in the secretion, into the
medium, of biologically active biosynthetic or rHGH that was identical to that naturally produced by our body – invention that gained an international patent.
1 A FDA report refers as the first achievement in personalized medicine the
approval on September of 1998 of Herceptin for the treatment of HER2 positive
metastatic breast cancers and on the same day of its companion test
HerceptTest to DAKO Corp (www.fda.gov/downloads/scienceresearch/
specialtopics/personalizedmedicine/ucm372421.pdf). However, our use of
the sequence of the hGH locus to develop a genetic test usable to predict re-
sponse to rHGH, published as a BSc thesis in 1994 and as a scientific paper in
1997 is, to the best of our knowledge, the first such achievement and thus the
detonator of the era of the so-called personalized medicine.
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designed companion diagnostic test was invented. The test was just
perfect, since, in addition to only needing a single pair of PCR con-
sensus primers for simultaneously amplifying each of the five genes in
the hGH locus, it sufficed to follow the PCR with a digestion with a
single restriction enzyme to reveal if the gene coding for HGH (hGH-N)
was present or not in the patient's genome. Moreover, and to add to its
elegance, it also identified, among the amplified products, the one re-
sponsible for the placental counterpart of this hormone (hGH-V), and its
presence in the gel used to resolve the digested products acted as an
internal control to demonstrate that the test had technically worked.
This feature was quite convenient, since, as Carl Sagan used to say:
“absence of evidence is not necessarily evidence of absence,” and this
“internal control gene” detection feature of our test, made life simpler
in diagnostic laboratories with only modest molecular biology infra-
structure.
This genomic information-based diagnostic test not only served as
the companion diagnostic for this inaugural product of modern bio-
technology, rHGH, but also as a versatile tool to investigate gene al-
terations in the rest of the genes of the hGH locus, soon to be proven
when explaining the extremely rare condition of total absence of CSH in
an otherwise uneventful pregnancy having found in such cases that
gene deletions of the CSH genes are their common underlying causes
[9].
So, catapulted by our research passion, surrounded by talented
youth, trying to revert a scientific gap and to cope with a health dis-
parity, and on top of that, provoked by our pride to prove science is the
most powerful tool to advance medicine, we had made world-pioneer
discoveries and inventions that contributed to the dawn of at least two
monumental historical enterprises of the life sciences of the last half of a
century: the Human Genome Project and Personalized Medicine (see
Table 1).
While the Human Genome Project has revolutionized biomedical
research and detonated waves of new biotech start-ups, Personal or
Precision Medicine has become a global aim of governments to cope
with the unsustainable rise of expenditure in health and to drastically
reduce the estimated approximately 10% of the unnecessary hospitali-
zations due to adverse effects because of errors in drug prescriptions
and in their dosing.
We, as others like us in the world daring to dream of doing world-
class science in their adverse scenarios, are kept encouraged by our
string of achievements, as modest as they might be. With them, and if
we persevere, we ended up touching the lives of many. First, of youth
venturing themselves in science. Second, of responsible and even heroic
health professionals wishing to offer more relief to the disease burden
of their patients. And third, of brave men and women wanting to use
science to create businesses and better jobs to help revert the limita-
tions of the local scientific capabilities and the disparities of our af-
flicted contemporaries. If we persist and see the day come when our
dreams are fulfilled, we must feel extremely lucky and proud of having
paid back part of our debt to society, for the enormous privilege of
having been trained in academic centers of excellence to join the army
of men and women advancing medicine with the torch of science.
Fig. 7. A genetic test to identify HGH-deficient pa-
tients that would not respond to replacement therapy
from those that would. Bioinformatic analyses of the
sequences of the five genes of the hGH locus allowed
us to design a simple polymerase chain reaction with
just one pair of consensus primers to amplify them.
Digestion of the mixture of amplicons with Acc1 re-
striction enzyme should render four digestion pro-
ducts as a ladder of bands: the first and last bands are
digestion products of the gene responsible, in the
hypophysis, for the synthesis of HGH (hGH-N), while
the second and third bands are evidence of the pre-
sence of the placental gene counterpart (hGH-V).
Moreover, these last conveniently act as an internal
control to verify the test worked fine (they should
always be present).
Table 1
Timeline and history of personalized medicine.
Genome and personalized medicine: milestones
1. More than two and a half millennia ago Hippocrates stated: “it's far more
important to know what person the disease has than what disease the person has”
2. In 1956, “favism,” the genetic basis for the selective toxicity of fava beans, was
discovered to be due to a deficiency in the metabolic enzyme G6PD
3. In 1985, Renato Dulbecco realized that, in order to advance cancer research, it
was necessary to sequence the human genome
4. In 1988, our laboratory joined colleagues from Genentech, Inc, in sequencing the
entire hGH locus (a world record), making evident the feasibility of sequencing
the Human Genome
5. In 1990, the Human Genome Project (HGP) was launched and the first draft was
published in 2001, while its final version in 2003
6. Since the early 1990s, individualized treatments tailored to the genome of each
patient were envisioned but rarely realized
7. In 1994, our laboratory designed a diagnostic test for the prediction of the success
of rHGH replacement therapy, being the earliest registry of a Companion
Molecular Diagnostics (CMDx) test ever invented
8. In 1998 when FDA approved Herceptin (anti-EGFR mAb for EGFR+ breast
tumors) and HerceptTest (to detect such tumors) it became the first “official”
CMDx invented
9. Since then, a growing list of diagnostic packages/personalized medicine therapies
has received, from the FDA, labels recognizing and recommending them
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